NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Angiocrine Bioscience

Angiocrine Bioscience

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://angiocrinebioscience.com/

Last Round

VC Round

Sep 4, 2025

Total Funding Raised

$45.83M

Company Overview

Angiocrine Bioscience is a biotechnology company that develops a curative cellular therapies platform aimed at treating conditions in regenerative medicine and hematopoietic stem cell gene therapy.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

cell therapyengineered endothelial cellE-CELregenerative medicinestem cell transplantationhematopoietic recoveryAB-205biotechgene therapytissue repairclinical stage biotechoncology therapyhematologyadvanced therapy medicinal productATMP

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Angiocrine Bioscience Comparables

Compare Angiocrine Bioscience with similar companies based on industry and business-model similarity.

Angiocrine Bioscience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Angiocrine Bioscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundSep 4, 2025
GrantDec 19, 2022
GrantDec 15, 2022
Series BMar 29, 2022
GrantAug 24, 2017
Grant
Feb 23, 2017

Key People

Founding team and executive leadership

John Lomoro

Chief Financial Officer

Executive Team

Angiocrine Bioscience Investors

Notable investors and investment history

Angiocrine Bioscience investors
InvestorRounds
Good Growth CapitalSeries B
California Institute for Regenerative MedicineGrant
Cobro VenturesSeries B

Angiocrine Bioscience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Angiocrine Bioscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Angiocrine Bioscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range14
Year Founded2012
Last FundingSep 4, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.